REG - Solvonis Therapeutic - Publication of a Prospectus

Solvonis TherapeuticsAnnouncement

21/05/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU6521Ja&default-theme=true

RNS Number : 6521J  Solvonis Therapeutics PLC  21 May 2025

21 May 2025

 

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

Publication of a Prospectus

 

Solvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company
co-developing therapeutics for mental health disorders, is pleased to announce
that, further to the announcements released by the Company on 15 May 2025 and
16 May 2025, it has today published a prospectus pursuant to the Prospectus
Regulation Rules made by the Financial Conduct Authority ("FCA") under Part VI
of FSMA (the Financial Services and Markets Act 2000, as amended) (the
"Prospectus").

 

The Prospectus, which has been approved by the FCA, will be available shortly
on the Company's website at www.solvonis.com (http://www.solvonis.com/) and
will also be available at the FCA's National Storage Mechanism at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries:

 

 Solvonis Therapeutics plc                                      anthony@solvonis.com
 Anthony Tennyson, CEO & Executive Director

 Allenby Capital Limited (Financial Adviser and Joint Broker)   +44 (0) 20 3328 5656
 Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

 Guy McDougall (Sales & Corporate Broking)

 Singer Capital Markets Limited (Joint Broker)                  +44(0) 20 7496 3000
 Phil Davies / Patrick Weaver

 

 

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on
developing intellectual property related to the treatment of mental health and
substance use disorders, and co-developing therapeutics for mental health
disorders. Solvonis' mission is to improve outcomes for individuals suffering
from mental health disorders, with an initial focus on trauma-related mental
health conditions, such as PTSD. PTSD affected approximately 13 million adults
in the U.S. in 2020, with the Company estimating a current affected population
of 20 million across the U.S., UK, and key EU markets.

www.solvonis.com (http://www.solvonis.com/)  | LinkedIn
(http://www.linkedin.com/company/solvonis)  | X (formerly Twitter)
(https://x.com/SolvonisTx)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PDIMZGZKDMVGKZM